Search
Posaconazole
go.drugbank.com/drugs/DB01263ApprovedInvestigationalVet approvedPosaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Fusidic acid
go.drugbank.com/drugs/DB02703ApprovedInvestigationalIt is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections. … (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.
VLTS-589
go.drugbank.com/drugs/DB05430InvestigationalVLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Lincomycin
go.drugbank.com/drugs/DB01627ApprovedInvestigationalVet approved[A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964.[L33214] … [A190621] Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains
Black cohosh
go.drugbank.com/drugs/DB13975ApprovedInvestigational[L2303] Hormone replacement therapy (HRT) is the standard treatment for early symptoms in post-menopausal women, however, increases the risk of stroke, heart diseases, as well as breast cancer in older … [A32543] The American College of Obstetrics and Gynecology guidelines on the use of botanicals, such as black cohosh, for the management of menopausal symptoms the use of for up to six months, especially
Brimonidine
go.drugbank.com/drugs/DB00484ApprovedInvestigational[A178948,A178969] Ophthalmically, brimonidine is used to lower intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. … [A178948] The topical form of brimonidine was approved by the FDA in August 2013 for the symptomatic treatment of persistent facial erythema of rosacea in adults.
Talazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigational[L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020.
Trovafloxacin
go.drugbank.com/drugs/DB00685ApprovedWithdrawnIt exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. … Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer.
Ioxitalamic acid
go.drugbank.com/drugs/DB13444ApprovedWithdrawn[A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995. … [A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg.
Flupentixol
go.drugbank.com/drugs/DB00875ApprovedInvestigationalWithdrawnIt is approved for use in Canada and other countries around the world, but not in the US. … Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid.